PRTK News and Press, Paratek Pharmaceuticals Inc. From 06/27/23

NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital PR Newswire Intends to Withhold Its Votes Against All Three Board Members Up for Election at the Annual Meet...

MONSEY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $2.15 per share in cash, plus a contingent value right (CVR), at which Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) (“Paratek”) has agreed to be sold to Gurne...

NEW YORK, NY / ACCESSWIRE / June 18, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: VectivBio Holding AG (NASDAQ:VECT)...

BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, governme...

2023-06-06 10:40:57 ET Antibiotic developer Paratek Pharmaceuticals ( NASDAQ: PRTK ) has agreed to be taken private by Gurnet Point Capital and Novo Holdings, the investment arm of the Novo Nordisk Foundation, for up to approximately $462M. Under the deal, the investment firms w...

Transaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3.00 per Share of Common Stock, Including Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 on Achievement of a Commercial Milestone Total Transa...

2023-06-01 15:18:45 ET Paratek Pharmaceuticals ( NASDAQ: PRTK ) soared 16% amid a report about one of the potential private equity buyers for the biopharma company. Gurnet Point Capital is said to be one of the PE firms circling the company, according to a Betaville ...

2023-05-09 20:00:07 ET Paratek Pharmaceuticals, Inc. (PRTK) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Sarah Higgins - Vice President, Finance, Controller and Principal Accounting Officer Evan Loh - Chief Executive Officer, Director ...

2023-05-09 16:35:49 ET Paratek Pharmaceuticals press release ( NASDAQ: PRTK ): Q1 GAAP EPS of -$0.35 beats by $0.03 . Revenue of $31.24M (+25.7% Y/Y) misses by $0.39M . 2023 revenue guidance of $143 to $158 million vs $158.97M consensus Consistent with...

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidanc...